Herpes simplex virus type 2 and HIV disease progression: A systematic review of observational studies

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Tan, Darrell Hoi San ^a,b,c,d   Murphy, Kellie ^d,e   Shah, Prakesh ^d,f   Walmsley, Sharon L ^b,c,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

CD4 count; Disease progression; Herpes simplex virus; Human immunodeficiency virus; Seropositivity; Systematic review; Viral load

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; SYSTEMATIC REVIEW; TIME TO TREATMENT; TREND STUDY; VIRUS INHIBITION; VIRUS LOAD; BLOOD; GENITAL HERPES; ISOLATION AND PURIFICATION; PATHOLOGY; VIROLOGY;

CD4 LYMPHOCYTE COUNT; COINFECTION; DISEASE PROGRESSION; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 84886110362     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-502     Document Type: Article

References (34)

1. Romanowski B, Myziuk LN, Walmsley SL, Trottier S, Singh AE, Houston S, Joffe M, Chiu I. Seroprevalence and risk factors for Herpes Simplex virus infection in a population of HIV-infected patients in Canada. Sex Transm Dis 2008, 36:165-169.
2. Gray RH, Li X, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, Lutalo T, Kiwanuka N, Kigozi G, Nalugoda F, et al. Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis 2004, 189:1209-1215. 10.1086/382750, 15031789.
3. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, Margolick JB, Phair JP, Mellors JW. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000, 181:872-880. 10.1086/315339, 10720507.
4. Strick LB, Wald A, Celum C. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis 2006, 43:347-356. 10.1086/505496, 16804851.
5. Reynolds SJ, Makumbi F, Newell K, Kiwanuka N, Ssebbowa P, Mondo G, Boaz I, Wawer MJ, Gray RH, Serwadda D, et al. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. Lancet Infect Dis 2012, 12:441-448. 10.1016/S1473-3099(12)70037-3, 3420068, 22433279.
6. Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E, et al. Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010, 375:824-833. 10.1016/S0140-6736(09)62038-9, 2877592, 20153888.
7. McMahon MA, Siliciano JD, Lai J, Liu JO, Stivers JT, Siliciano RF, Kohli RM. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008, 283:31289-31293. 10.1074/jbc.C800188200, 2581555, 18818198.
8. Lisco A, Vanpouille C, Tchesnokov EP, Grivel JC, Biancotto A, Brichacek B, Elliott J, Fromentin E, Shattock R, Anton P, et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008, 4:260-270. 10.1016/j.chom.2008.07.008, 18779052.
9. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007, 147:573-577. 10.7326/0003-4819-147-8-200710160-00010, 17938396.
10. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007, 147:W163-W194.
11. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007, 36:666-676. 10.1093/ije/dym018, 17470488.
12. Barnabas RV, Wasserheit JN, Huang Y, Janes H, Morrow R, Fuchs J, Mark KE, Casapia M, Mehrotra DV, Buchbinder SP, et al. Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). J Acquir Immune Defic Syndr 2011, 57:238-244. 10.1097/QAI.0b013e31821acb5, 3446850, 21860356.
13. Cachay ER, Frost SDW, Richman DD, Smith DM, Little SJ. Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection [see comment]. J Infect Dis 2007, 195:1270-1277. 10.1086/513568, 17396995.
14. Cachay ER, Frost SDW, Poon AFY, Looney D, Rostami SM, Pacold ME, Richman DD, Little SJ, Smith DM. Herpes simplex virus type 2 acquisition during recent HIV infection does not influence plasma HIV levels. J Acquir Immune Defic Syndr 2008, 47:592-596. 10.1097/QAI.0b013e318163bd87, 2630881, 18197122.
15. Crum-Cianflone N, Hale B, Truett A, Utz G, Chun H, Pope B, Burgi A, Medina S, Brandt C, Furtek K, et al. The effect of herpes simplex virus 2 (HSV2) co-infection in HIV-infected persons on CD4 counts, HIV viral load, and time to antiretroviral medications. 44th Annual Meeting of IDSA: 12-15 October 2006; Abstract 895 2006, Toronto, Canada: Alexandria: Infectious Diseases Society of America.
16. Nagot N, Ouedraogo A, Konate I, Weiss HA, Foulongne V, Defer MC, Sanon A, Becquart P, Segondy M, Sawadogo A, et al. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis 2008, 198:241-249. 10.1086/589621, 18593294.
17. Roxby AC, Drake AL, John-Stewart G, Brown ER, Matemo D, Otieno PA, Farquhar C. Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women. PLoS One 2011, 6:e19947. 10.1371/journal.pone.0019947, 3102671, 21637835.
18. Suligoi B, Dorrucci M, Volpi A, Andreoni M, Pezzotti P, Rezza G, Italian Seroconversion S Absence of an effect of herpes simplex virus type 2 infection on HIV disease progression: data from a cohort of HIV-positive individuals with known date of seroconversion. AIDS 2001, 15:133-135. 10.1097/00002030-200101050-00024, 11192860, Italian Seroconversion S.
19. Ludema C, Cole SR, Poole C, Chu H, Eron JJ. Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2. AIDS 2011, 25:1265-1269. 10.1097/QAD.0b013e328347fa37, 21666542.
20. Ioannidis JP, Collier AC, Cooper DA, Corey L, Fiddian AP, Gazzard BG, Griffiths PD, Contopoulos-Ioannidis DG, Lau J, Pavia AT, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998, 178:349-359. 10.1086/515621, 9697714.
21. Ashley-Morrow R, Krantz E, Wald A. Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex Transm Dis 2003, 30:310-314. 10.1097/00007435-200304000-00007, 12671550.
22. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988, 26:662-667. 266403, 2835389.
23. Ramaswamy M, Sabin C, McDonald C, Smith M, Taylor C, Geretti AM. Herpes simplex virus type 2 (HSV-2) seroprevalence at the time of HIV-1 diagnosis and seroincidence after HIV-1 diagnosis in an ethnically diverse cohort of HIV-1-infected persons. Sex Transm Dis 2006, 33:96-101. 10.1097/01.olq.0000187211.61052.c7, 16432480.
24. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994, 121:847-854. 10.7326/0003-4819-121-11-199412010-00004, 7978697.
25. Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 1999, 131:14-20. 10.7326/0003-4819-131-1-199907060-00004, 10391810.
26. Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003, 30:174-177. 10.1097/00007435-200302000-00015, 12567178.
27. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995, 333:770-775. 10.1056/NEJM199509213331205, 7643884.
28. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997, 176:766-770. 10.1086/517297, 9291329.
29. Aumakhan B, Gaydos CA, Quinn TC, Beyrer C, Benning L, Minkoff H, Merenstein DJ, Cohen M, Greenblatt R, Nowicki M, et al. Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. PLoS One 2010, 5:1-7.
30. Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial. J Infect Dis 2011, 204:1912-1917. 10.1093/infdis/jir649, 3247811, 21998479.
31. Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N, et al. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. J Infect Dis 2011, 203:117-121. 10.1093/infdis/jiq013, 3024584,3024584, 21148504.
32. Roxby AC, Liu AY, Drake AL, Kiarie JN, Richardson B, Lohman-Payne BL, John-Stewart GC, Wald A, De Rosa S, Farquhar C. Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir. AIDS Res Hum Retroviruses 2013, 29:94-98. 10.1089/aid.2012.0071, 22852760.
33. Yi TJ, Walmsley S, Szadkowski L, Raboud J, Rajwans N, Shannon B, Kumar S, Kain KC, Kaul R, Tan DHS. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/Herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy. Clin Infect Dis 2013, epub ahead of print.
34. Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clin Microbiol Infect 2004, 10:530-536. 10.1111/j.1469-0691.2004.00836.x, 15191381.